Radioligand CDMO Services

Radioligand Services

Sophia provides Radioligand CDMO Services for sponsors developing targeted radiopharmaceutical products across oncology, diagnostics, theranostics, precision imaging, targeted radionuclide therapy, alpha-emitting therapies, beta-emitting therapies, PET tracers, SPECT tracers, peptide radioligands, antibody radioconjugates, small molecule ligands, and next-generation nuclear medicine platforms.

Radioligands are not ordinary drugs. They are targeted molecules carrying radioactive payloads. The molecule must find the biological target. The chelator must hold the radionuclide. The isotope must decay with the right physics. The formulation must remain stable. The product must be sterile or prepared under suitable controls. The dose must be released quickly enough to matter before radioactive decay takes too much value away. The logistics must work. The quality control must be fast, precise, and unforgiving.

This is why Radioligand CDMO services require a different kind of manufacturing discipline. Normal biologics and small molecule timelines can be slow and methodical. Radiopharmaceuticals introduce a clock. Half-life is not a metaphor. It is the product disappearing in real time.

Sophia supports radioligand programmes through chelator-linker review, ligand developability, isotope selection strategy, radiolabelling process development, radionuclide supply coordination, cold precursor development interface, hot synthesis planning, purification, sterile filtration feasibility, radiochemical purity testing, identity testing, endotoxin and sterility strategy, formulation, stability, decay correction, batch documentation, radiation safety alignment, GMP/GMP-like readiness, and clinical supply planning.

The platform is built for targeted products where chemistry, biology, physics, quality, and logistics all have to land at once.

Why Radioligands Matter

Radioligands matter because they connect molecular targeting with nuclear decay. A ligand binds a target associated with disease. The radionuclide emits radiation that can be detected for imaging or used to damage diseased tissue. The same biological target can sometimes support both diagnosis and therapy, which is why the theranostic model has become so important in nuclear medicine.

In diagnostics, radioligands can help visualise disease distribution, receptor expression, target availability, treatment eligibility, and response. In therapy, radioligands can deliver beta, alpha, Auger, or other emissions to target-positive cells. Oncology has been the main driver, especially prostate cancer, neuroendocrine tumours, and emerging solid tumour targets. The FDA approved lutetium-177 vipivotide tetraxetan, known commercially as Pluvicto, for PSMA-positive metastatic castration-resistant prostate cancer in 2022, and expanded the indication in 2025 for certain patients after androgen receptor pathway inhibitor therapy where delaying taxane chemotherapy is appropriate.

That public clinical momentum has made radioligand development one of the most technically attractive areas in advanced therapeutics. It is also one of the least forgiving. A radioligand product must be designed for target binding, chelation, isotope compatibility, radiochemical yield, radiochemical purity, specific activity, molar activity, stability, sterility, endotoxin control, radiation safety, shipping, decay, and patient-dose timing.

A weak radioligand is not saved by good branding. It has to work chemically and logistically.

A Short History of Radioligand Therapy

The roots of radiopharmaceutical development go back to the early history of radioactivity, nuclear medicine, iodine therapy, and tracer science. Radioiodine became one of the earliest major examples of targeted nuclear medicine because thyroid tissue naturally concentrates iodine. That simple biological fact created a therapeutic and diagnostic pathway.

Later, nuclear medicine expanded through technetium-based imaging, PET tracers such as fluorodeoxyglucose, peptide receptor radionuclide therapy, monoclonal antibody radioconjugates, and targeted small molecule radioligands. The field moved from organ-level targeting toward molecular targeting. Instead of relying only on tissue uptake patterns, developers began designing ligands to bind receptors, transporters, antigens, enzymes, or tumour-associated proteins.

The modern radioligand era is defined by theranostics. A diagnostic isotope can be used to image a target. A therapeutic isotope can then be attached to a related ligand to treat target-positive disease. Gallium-68 and fluorine-18 may support PET imaging. Lutetium-177 may support beta therapy. Actinium-225 and other alpha emitters are being explored for highly potent targeted alpha therapy. IAEA technical work has described actinium-225 as an alpha-emitting radionuclide receiving significant attention for oncological treatment applications.

The history shows the direction: nuclear medicine is becoming more targeted, more molecular, more personalised, and more manufacturing-dependent. The drug is not only the ligand. It is the ligand, isotope, chelator, quality control method, radiation safety system, and supply chain together.

The Chemistry of Radioligands

A radioligand usually contains several functional parts: a targeting moiety, a linker, a chelator or prosthetic group, and a radionuclide. Each part influences the final product.

The targeting moiety may be a small molecule, peptide, antibody, antibody fragment, nanobody, affibody, minibinder, or other binder. Its job is to recognise the biological target. Affinity matters, but so do internalisation, clearance, tumour penetration, plasma protein binding, off-target distribution, kidney uptake, liver uptake, and metabolic stability.

The linker connects the targeting moiety to the chelator or radionuclide-bearing group. Linkers can change hydrophilicity, charge, flexibility, plasma stability, biodistribution, renal clearance, and target retention. A tiny linker change can move uptake from tumour to kidney or from blood to liver. Radiochemistry is fussy like that.

The chelator holds the radionuclide. DOTA, NOTA, NODAGA, DFO, TETA, sarcophagine-type chelators, macropa-like chelators, and other systems may be used depending on isotope. The chelator must bind the metal strongly under radiolabelling conditions and remain stable in vivo. A chelator that looks fine in a vial but releases radionuclide in the body is not acceptable.

The radionuclide provides the signal or therapy. Lutetium-177 emits beta particles and gamma photons useful for imaging and dosimetry support. Actinium-225 emits alpha particles through a decay chain and can deliver very high linear energy transfer over short path lengths. Gallium-68 and copper-64 support PET imaging. Zirconium-89 is often used for longer-lived immuno-PET applications. Iodine isotopes, terbium isotopes, scandium isotopes, lead isotopes, and other radionuclides may support different development strategies.

The chemistry is elegant, but it has no patience for sloppiness. A successful Radioligand CDMO Services programme must control the entire molecular system.

Radioligand Product Types Supported

Sophia supports Radioligand CDMO services across diagnostic, therapeutic, and theranostic products.

Therapeutic radioligand products may include Lu-177 peptide or small molecule therapies, Ac-225 targeted alpha therapies, radiolabelled antibodies, radiolabelled antibody fragments, PSMA-directed ligands, somatostatin receptor ligands, fibroblast activation protein inhibitor concepts, gastrin-releasing peptide receptor ligands, integrin-targeted ligands, CXCR4-targeted ligands, tumour antigen radioconjugates, and next-generation targeted radionuclide therapy candidates.

Diagnostic radioligands may include Ga-68 PET tracers, F-18 labelled ligands, Cu-64 tracers, Zr-89 immuno-PET products, Tc-99m SPECT ligands, I-123 or I-124 labelled products, and companion diagnostic candidates.

Theranostic programmes may pair diagnostic and therapeutic isotopes around the same or related targeting moiety. These programmes require careful comparability of target binding, biodistribution, dosimetry logic, chelator compatibility, and clinical development plan.

Research and translational programmes may require cold precursor synthesis interface, non-radioactive reference standards, analytical standards, radiolabelling feasibility, small-scale hot runs, stability screening, and early toxicology material planning.

The common requirement is controlled radiochemistry. The isotope changes the physics. The chemistry still has to behave.

Isotope Selection Strategy

Sophia supports isotope selection strategy for radioligand programmes. The isotope should match the biological target, disease setting, molecule pharmacokinetics, intended use, route, and supply chain.

For small molecules and peptides that clear quickly, shorter-lived isotopes may be suitable for imaging, while therapeutic isotopes must match target uptake and retention. For antibodies, longer circulation may require longer-lived imaging isotopes such as Zr-89, while therapeutic antibody radioconjugates may need careful marrow exposure and dosimetry management. For fast-clearing fragments or nanobodies, isotope half-life and renal exposure become central.

Beta emitters such as Lu-177 can support crossfire effects over a certain tissue range, which may be useful for heterogeneous tumours. Alpha emitters such as Ac-225 can deliver high-energy radiation over very short distances, which may be powerful but requires careful control of daughter isotopes, chelation, dosimetry, and safety. Practical implementation of Ac-225 radiopharmaceuticals has been described as technically challenging because alpha-emitting radionuclides raise specific methodological and operational issues.

Supply also matters. A brilliant isotope that is not reliably available is a commercial problem. Generator systems, reactor production, cyclotron production, isotope purity, specific activity, shipping time, and regional access all influence product development.

In radioligands, isotope selection is not a late choice. It is part of product design.

Chelator, Linker, and Precursor Development

Sophia supports chelator-linker and precursor development strategy for radioligand products. This includes chelator selection, linker design, cold precursor purity, reference standard planning, metal-free conditions, trace-metal control, conjugation chemistry, ligand integrity, and analytical method development.

Radiolabelling performance depends heavily on precursor quality. Trace metals can compete with the desired radionuclide. Poor precursor purity can reduce radiochemical yield. Linker instability can create impurities. Chelator chemistry must match isotope coordination preferences. The cold precursor must be manufactured, characterised, stored, and released properly.

For peptide radioligands, solid-phase peptide synthesis, linker installation, chelator coupling, purification, counterion control, and peptide stability matter. For small molecule radioligands, synthetic route, impurity profile, chelator attachment, stereochemistry, and solubility may be central. For antibody radioconjugates, bioconjugation chemistry, chelator-to-antibody ratio, aggregation, immunoreactivity, and stability become critical.

A radioligand is usually made twice: first as a non-radioactive precursor, then as the radioactive final product. If the precursor is poor, the hot product will not become good by miracle.

Radiolabelling Process Development

Sophia provides Radioligand CDMO Services for radiolabelling process development. The process must produce the desired radiolabelled product with adequate yield, radiochemical purity, stability, and reproducibility within the isotope’s time constraints.

Development may include buffer selection, pH, temperature, reaction time, precursor concentration, isotope activity, molar activity, metal impurity control, reducing agents, antioxidants, purification method, sterile filtration feasibility, final formulation buffer, and decay-corrected yield.

Radiolabelling conditions must be gentle enough to preserve the ligand but strong enough to form the metal-chelate complex or labelled product. Peptides may tolerate heating. Antibodies may not. Small molecules may have solubility issues. Alpha emitters may require special handling. Some radionuclides may require post-labelling purification. Some products may be prepared in automated synthesis modules. Others may require bespoke hot-cell workflows.

The radiolabelling method should be robust, not heroic. If every batch depends on one wizard’s hands, the process is not ready.

Purification and Sterile Preparation

Radioligand purification must remove unbound radionuclide, radiochemical impurities, precursor-related impurities, degraded ligand, solvents, buffers, metals, and process residuals while preserving product activity and timing.

Sophia supports purification strategies including solid-phase extraction, HPLC purification where appropriate, cartridge purification, ultrafiltration for larger conjugates, buffer exchange, sterile filtration feasibility, aseptic processing considerations, and final dose preparation.

Sterile preparation is central because many radioligands are injectable products. The EANM current good radiopharmacy practice guideline is structured around EU GMP principles for small-scale radiopharmaceutical preparation, reflecting the quality expectations around personnel, premises, equipment, production, quality control, and documentation.

Radiopharmaceutical sterility testing may not always be complete before product release because of short half-life. That means aseptic process control, environmental controls, filter integrity, endotoxin testing, bioburden strategy, and validated or justified release procedures become essential. The clock does not excuse weak quality. It requires smarter quality.

Quality Control and Release Testing

Sophia supports QC strategy for radioligand CDMO services, including rapid, radiopharmaceutical-appropriate testing. Quality control may include appearance, pH, radiochemical purity, radionuclidic identity, radionuclidic purity, radioactive concentration, total radioactivity, molar activity, chemical purity, residual solvents, residual precursor, endotoxin, sterility strategy, filter integrity, identity testing, stability, and dose calibrator checks.

Analytical methods may include radio-HPLC, radio-TLC, gamma spectroscopy, dose calibrator measurements, ICP-MS for selected metal impurities, LC-MS for precursor and reference standards, UV-HPLC, endotoxin testing, sterility testing, and product-specific binding or cell uptake assays during development.

The release strategy must reflect half-life. Ga-68 products demand speed. Lu-177 products allow more time but still require efficient release. Ac-225 products require special care because alpha emissions, daughter radionuclides, and radiochemical stability create additional complexity. Antibody radioconjugates may have longer windows but more complex biologics analytics.

A radioligand batch is a perishable batch. QC has to be quick without being loose.

Formulation and Stability

Sophia supports formulation development for radioligand products, including buffer selection, pH, isotonicity, stabilisers, antioxidants, radiolysis control, metal chelation control, container compatibility, adsorption prevention, dilution stability, transport stability, and shelf-life strategy.

Radiolysis is one of the signature problems in radiopharmaceutical formulation. The product’s own radiation can generate reactive species that degrade the ligand. Stabilising excipients such as ascorbate, gentisate, methionine, ethanol, or other scavengers may be considered depending on product and route. The formulation must also preserve radiochemical purity, target binding, sterility, pH, osmolality, and container compatibility.

For peptide radioligands, stability may be limited by radiolysis, oxidation, dechelation, or peptide degradation. For antibody radioconjugates, aggregation, immunoreactivity, radiolysis, and protein stability matter. For alpha emitters, daughter recoil and chelation stability may create special formulation concerns.

Stability must be tested under real conditions: activity concentration, storage temperature, container type, time, transport, and final dilution. A room-temperature low-activity test may not predict a clinical high-activity batch.

The product has a clock. Formulation is how it keeps its composure.

Facilities, Shielding, and European Execution

Radioligand manufacturing needs specialised infrastructure: hot cells, shielding, radiation monitoring, automated synthesis modules, controlled environments, dose calibrators, contamination controls, waste handling, trained personnel, and qualified QC equipment. Facility design influences what isotopes can be handled, what batch sizes are practical, what release testing can be performed, and how safely work can proceed.

Sophia’s European model is being developed around state-of-the-art technical execution, with Spain and Switzerland positioned as high-discipline facility geographies for advanced radiopharmaceutical coordination, sterile product thinking, analytical control, and cross-border clinical supply planning. This matters because radioligand work is regional by nature. Isotope half-life, transport lanes, hospital access, customs procedures, release timing, and country-specific requirements can all affect the practical viability of a programme.

Spain brings a strong clinical and hospital-linked nuclear medicine environment within Europe. Switzerland brings precision manufacturing culture, pharmaceutical quality discipline, and central European connectivity. The brand logic is understated but important: radioligands need more than lab skill. They need a European operating model that can handle science, quality, timing, and logistics without theatre.

In this field, being late is not charming. It is decay.

Radiation Safety and Operational Control

Sophia supports radiation safety planning for radioligand programmes, including isotope handling, operator exposure, shielding, contamination control, environmental monitoring, radioactive waste, transport classification, documentation, and emergency procedures.

Radiation safety depends on isotope type. Positron emitters, gamma emitters, beta emitters, and alpha emitters create different risks. Lu-177 handling differs from Ga-68. Ac-225 differs from both. Shielding materials, dose rates, contamination monitoring, waste decay storage, vial handling, automated modules, and personnel training must fit the isotope.

Operational control also includes batch scheduling. Radiopharmaceutical manufacturing cannot behave like ordinary inventory. Production, QC, release, transport, and administration must align. Generator elution, isotope delivery, synthesis slot, QC completion, pharmacist release, courier handoff, and clinical administration all sit inside one fragile timeline.

The operational culture must be calm, fast, and exact. Not rushed. Exact.

GMP, CMC, and Regulatory Documentation

Sophia supports GMP/GMP-like and CMC documentation for radioligand programmes, including precursor control, radionuclide specifications, radiolabelling process description, synthesis module records, purification method, QC methods, release specifications, sterility strategy, endotoxin method, stability protocol, radiation safety documentation, batch records, CoA, deviation handling, change control, comparability, and clinical supply documentation.

EMA guidance pages identify radiopharmaceutical and diagnostic-agent guidelines as a specific scientific area for developers preparing marketing authorisation applications. For early clinical work, product documentation may also need to support investigational medicinal product dossiers, method validation, production controls, risk assessment, and radiopharmaceutical-specific release considerations.

CMC for radioligands must explain both drug chemistry and radioactivity. The dossier has to describe the non-radioactive precursor, radionuclide source, radiolabelling method, purification, formulation, quality control, stability, sterility strategy, and logistics. If the product is theranostic, the relationship between diagnostic and therapeutic ligands may also need explanation.

The paperwork is not decorative. It is how the half-life-driven process becomes reviewable.

Why Sophia for Radioligand CDMO Services

Sophia supports radioligand programmes through radiochemistry planning, chelator-linker strategy, isotope coordination, analytical development, sterile product interface, radiation safety documentation, formulation, and European clinical supply thinking. The platform is designed for sponsors who need radioligand development to move from promising target biology into controlled manufacturing.

The service includes:

Radioligand programme review
Diagnostic, therapeutic, and theranostic strategy
Ligand, linker, and chelator development support
Lu-177, Ac-225, Ga-68, Cu-64, Zr-89, I-123/I-124/I-131, Tc-99m, and emerging isotope planning
Cold precursor and reference standard interface
Radiolabelling process development
Radiochemical yield and purity optimisation
Purification and sterile preparation strategy
Radio-HPLC, radio-TLC, radionuclidic identity, and purity testing
Endotoxin and sterility strategy
Radiolysis control and formulation development
Stability and transport simulation
Radiation safety documentation
GMP/GMP-like batch documentation
Spain and Switzerland-linked European execution planning
Clinical supply and tech transfer support

The work is suited to products where the chemical structure, radioactive isotope, release test, sterile process, and delivery timeline all define success.

Technical Service Summary

Sophia provides Radioligand CDMO Services for targeted radiopharmaceuticals, radioligand therapies, theranostics, PET tracers, SPECT tracers, Lu-177 products, Ac-225 products, Ga-68 imaging agents, Cu-64 tracers, Zr-89 immuno-PET products, peptide radioligands, antibody radioconjugates, small molecule radioligands, and alpha or beta-emitting nuclear medicine products.

Relevant technical needs include chelator selection, linker strategy, isotope selection, radiolabelling, hot-cell workflow, automated synthesis module planning, radiochemical purity, radionuclidic purity, radio-HPLC, endotoxin testing, sterility strategy, radiolysis control, formulation, stability, radiation safety, release documentation, and clinical supply planning.

The service is intended for sponsors who need molecular targeting, isotope physics, radiochemistry, sterile preparation, and quality documentation to work as one product system.

FAQ: Radioligand CDMO Services

1. What are Radioligand CDMO Services?

Radioligand CDMO Services support development and manufacturing of targeted radiopharmaceutical products, including chelator-linker design, isotope strategy, radiolabelling, purification, QC, sterile preparation, formulation, stability, documentation, and clinical supply planning.

2. What is a radioligand?

A radioligand is a targeting molecule carrying a radioactive isotope. It may be used for imaging, therapy, or theranostic applications depending on the isotope and biological target.

3. What isotopes can radioligand programmes use?

Radioligand programmes may use Lu-177, Ac-225, Ga-68, Cu-64, Zr-89, I-123, I-124, I-131, Tc-99m, F-18, Tb isotopes, Sc isotopes, Pb isotopes, and other radionuclides depending on product strategy.

4. What is theranostics?

Theranostics combines diagnostic imaging and therapy around the same or related biological target. A diagnostic radioligand may identify target-positive disease, while a therapeutic radioligand delivers radiation to that target.

5. Why is chelator selection important?

The chelator holds the radioactive metal. Poor chelation can reduce yield, stability, safety, and in vivo performance. Chelator choice must match the radionuclide and product design.

6. What quality tests are used for radioligands?

Testing may include radiochemical purity, radionuclidic identity, radionuclidic purity, radioactivity concentration, molar activity, pH, appearance, residual solvents, residual precursor, endotoxin, sterility strategy, and stability.

7. Why is radioligand manufacturing time-sensitive?

Radioactive isotopes decay over time. The product loses activity according to its half-life, so synthesis, QC, release, transport, and administration must be tightly coordinated.

8. Can Sophia support alpha-emitting radioligands?

Yes. Sophia supports alpha-emitting radioligand development strategy, including Ac-225 planning, chelation review, radiolabelling, QC strategy, formulation, safety documentation, and development pathway design.

9. Can radioligands be antibody-based?

Yes. Antibody radioconjugates and immuno-PET products may use antibodies or fragments linked to radionuclides through chelators. These products require biologics, conjugation, radiochemistry, and stability expertise.

10. What should sponsors provide to begin a radioligand project?

Useful starting information includes target, ligand structure, chelator, isotope preference, precursor data, reference standard data, intended use, route, desired activity, radiolabelling data, stability data, and development stage.

Conclusion

Sophia provides Radioligand CDMO services for sponsors developing targeted radiopharmaceuticals, radioligand therapies, theranostic products, PET tracers, SPECT tracers, peptide radioligands, antibody radioconjugates, alpha therapies, beta therapies, and next-generation nuclear medicine products.

Radioligands are powerful because they combine molecular targeting with radioactive decay. They are difficult because the product must satisfy chemistry, isotope physics, sterile preparation, radiation safety, quality control, formulation, stability, logistics, and regulatory documentation at the same time. The ligand must bind. The chelator must hold. The isotope must match the biology. The radiolabelling process must be reproducible. The final product must remain stable and releasable within a half-life-driven timeline.

A complete Radioligand CDMO services programme may include ligand review, chelator-linker strategy, isotope selection, precursor control, radiolabelling development, purification, radiochemical purity testing, radionuclidic testing, endotoxin and sterility strategy, formulation, radiolysis control, stability, radiation safety documentation, GMP/GMP-like records, clinical supply planning, and European execution through Spain and Switzerland-linked infrastructure.

For sponsors developing Lu-177 therapies, Ac-225 targeted alpha therapies, Ga-68 diagnostics, Cu-64 tracers, Zr-89 immuno-PET products, peptide radioligands, antibody radioconjugates, or theranostic platforms, Sophia provides a controlled route from target biology to radiopharmaceutical product.

Email our team at info@sophiacdmo.com